Castration-resistant Prostate Cancer Clinical Trial
Official title:
A Multicenter Open Phase Ib to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Disitamab Vedotin in the Treatment With HER2- Expression, Gene Amplification or Mutation Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety and tolerance of Disitamab Vedotin in subjects with metastatic Castration-resistant prostate cancer.
This is an open-label, multicenter, Phase Ib Study designed to evaluate safety and efficacy of Disitamab Vedotin in the Treatment of Subjects with HER2- expression, gene amplification or mutation Metastatic Castration-Resistant Prostate Cancer. The study was designed with 2 cohorts, cohort 1 was planned to enroll 40 subjects who had not received paclitaxel at the mCRPC stage, and cohort 2 was planned to enroll 20 subjects who had received at least 1 paclitaxel at the mCRPC stage. Subjects received the experimental drug until disease progression, untolerance of toxicity, withdrawal, death, or discontinuation of the study by the Sponsor. After completion of study treatment (calculated from the date of the determination to discontinue treatment), all subjects will be followed for survival every 3 months (±14 days) until death, loss to follow-up, withdrawal of consent, or discontinuation of the study by Sponsor. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00974311 -
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
|
Phase 3 | |
Active, not recruiting |
NCT03700099 -
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
|
Phase 2 | |
Completed |
NCT02124668 -
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 2 | |
Completed |
NCT01634061 -
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
|
Phase 1 | |
Completed |
NCT01338831 -
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT03652493 -
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
|
Phase 2 | |
Recruiting |
NCT04549207 -
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
|
Phase 4 | |
Active, not recruiting |
NCT03305224 -
The Combination Therapy With Ra-223 and Enzalutamide
|
Phase 2 | |
Recruiting |
NCT04090528 -
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
Active, not recruiting |
NCT06193993 -
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
|
Phase 1 | |
Completed |
NCT02669771 -
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
|
||
Active, not recruiting |
NCT05084859 -
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03934164 -
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
|
||
Recruiting |
NCT03506997 -
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT03569280 -
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
|
Phase 1 | |
Enrolling by invitation |
NCT03356912 -
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
|
Phase 2 | |
Not yet recruiting |
NCT04148885 -
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 |